News / US / cnbc
Eli Lilly Crushes Q2 Expectations as Weight-Loss Drug Sales Skyrocket
Health Technology · Pharmaceuticals: Major · cnbc · 2026-08-05
NVO, NVO, LLY, LLYX, XLV, IBB, IHE, XLP, XPH, XBI
Eli Lilly reported strong second-quarter results, beating Wall Street estimates on the back of surging demand for its Mounjaro and Zepbound treatments.
What Happened
Earnings and Revenue Performance: Eli Lilly delivered a strong second-quarter performance, reporting adjusted earnings of $8.38 per share against the $6.01 expected by analysts. Total revenue reached $22.97 billion, significantly outpacing the $20.73 billion consensus estimate as prescription volumes climbed globally.
Blockbuster Drug Momentum: The company's weight-loss and diabetes portfolio continues to drive growth, with Mounjaro generating $9.94 billion in worldwide revenue. Zepbound also showed robust performance, contributing $4.93 billion in U.S. sales despite downward pressure on realized pricing from increased market access.
Strategic Financial Outlook: Management raised its 2026 revenue guidance to a range of $85 billion to $87 billion, reflecting confidence in sustained demand. While adjusted profit guidance was adjusted to account for $3.03 per share in acquisition-related charges, the underlying operational strength remains significant.
M&A and Market Expansion: Leveraging its current financial windfall, Eli Lilly is aggressively pursuing strategic acquisitions, including recent deals in the psychedelics and vaccine sectors. The company is also positioning itself to capitalize on expanded Medicare coverage for obesity medications throughout the remainder of the year.